Silencing of ADAM8 expression in hepatoma cells is associated with considerable suppression of these responses, suggesting that the specific inhibition of ADAM8 in future therapy regimens could optimize HCC therapy and prevent metastasis. The gene discussed is ADAM8; the disease is hepatocellular carcinoma.